

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: May 9, 2012.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2012-11745 Filed 5-14-12; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Development of Chemopreventive Treatments for Head and Neck Squamous Cell Carcinoma

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in PCT Patent Application No. PCT/US2009/054478, U.S. Patent Application No. 13/059,335 and foreign equivalents thereof entitled "Chemopreventive of Head and Neck Squamous Cell Carcinoma" (HHS Ref. No. E-302-2008/0) to Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd., which is located in Jerusalem, Israel. The patent rights in these inventions have been assigned to the United States of America.

Other than license applications submitted as objections to this Notice of Intent to Grant an Exclusive License, no further license applications will be considered for the exclusive field of use set forth below if the Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. is granted an exclusive license pursuant to this Notice of Intent to Grant an Exclusive License. The prospective exclusive license territory may be worldwide and the field of use may be limited to use of the Licensed Patent Rights for the prevention and treatment of head and neck cancers.

**DATE:** Only written comments and/or applications for a license which are

received by the NIH Office of Technology Transfer on or before June 14, 2012 will be considered, in addition to the current non-exclusive applications under consideration, for the prospective license territory and field of use to be granted under the contemplated exclusive patent license.

#### **FOR FURTHER INFORMATION CONTACT:**

Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Whitney A. Hastings, Ph.D., Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220; Email: [hastingsw@mail.nih.gov](mailto:hastingsw@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** In head and neck squamous cell carcinoma (HNSCC), a cancer occurring mostly in the mouth, it is frequently observed that the Akt/mTOR pathway is abnormally activated. Therefore, inhibiting this signaling pathway may help in treating this disease. Rapamycin and its analogs are known to inhibit the activity of mTOR so in principle they could serve as therapeutics for treating HNSCC.

This technology describes a method of potentially preventing or treating HNSCC through the inhibition of mTOR activity. The proof of this principle was demonstrated by rapid regression of mouth tumors in mice afflicted with Cowden syndrome with the administration of rapamycin. Like HNSCC, development of this disease is linked to over activation of the Akt/mTOR pathway. Furthermore, the therapeutic potential of rapamycin was demonstrated using mice in experiments that model chronic exposure to tobacco, which promotes the development of HNSCC. Therefore, inhibitors of mTOR have considerable potential in the prevention and treatment of HNSCC.

The prospective exclusive license and any further license applications received as objections to this Notice of Intent to Grant an Exclusive License, will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Any additional applications for a license in the field of use filed in

response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: May 9, 2012.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2012-11690 Filed 5-14-12; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Fiscal Year (FY) 2012 Funding Opportunity

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice of intent to award a single source grant to the University of California Los Angeles (UCLA).

**SUMMARY:** This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) intends to award approximately \$130,000 (total costs) for up to one year to the University of California Los Angeles (UCLA). This is not a formal request for applications. Assistance will be provided only to the University of California Los Angeles (UCLA) based on the receipt of a satisfactory application that is approved by an independent review group.

*Funding Opportunity Title:* TI-12-001.

*Catalog of Federal Domestic Assistance (CFDA) Number:* 93.243.

**Authority:** Foreign Operations and Related Programs Appropriations Act, 2010 (Division F, Pub. L. III-17). Funding for this program is made available through the State Department.

**Justification:** Only the University of California Los Angeles (UCLA) is eligible to apply. The Substance Abuse and Mental Health Services Administration (SAMHSA) is seeking to award a supplemental grant to the University of California Los Angeles (UCLA) to expand/enhance grant activities funded under the FY 2011 Cooperative Agreement for the Drug Demand Reduction Initiative for Iraq. This initiative builds on work begun as part of the 2010 Iraq-SAMHSA Initiative, which supported a team of

behavioral health professionals from the Government of Iraq (GOI Team) who visited substance abuse sites in the U.S. to learn about establishing substance abuse services and training.

The purpose of the supplemental funding is to provide logistical and fiscal management support, and training for project-related activities in Iraq, including SBIRT and other trainings planned to take place in Iraq.

At a minimum the funds awarded will be used to conduct the following activities:

- Develop a plan to provide logistical and fiscal management support for project-related activities in Iraq, including SBIRT and other trainings planned to take place in Iraq.

- Develop a plan for the United Nations Office on Drugs and Crime rapid assessment of the current substance use trends in Iraq and assist in the establishment of the Community Epidemiology Workgroup.

- Provide an implementation plan in the context of the overall project and an updated timeline, which shows how funds will be used to enhance logistics and financial management of the project.

- Provide a plan on how individuals served as a result of the supplemental activities will be incorporated into the ongoing Government Performance and Results Modernization Act of 2010 (GPRA) activities.

*Contact:* Shelly Hara, Substance Abuse and Mental Health Services Administration, 1 Choke Cherry Road, Room 8-1095, Rockville, MD 20857; telephone: (240) 276-2321; Email: [shelly.hara@samhsa.hhs.gov](mailto:shelly.hara@samhsa.hhs.gov).

**Cathy Friedman,**

*SAMHSA Public Health Analyst.*

[FR Doc. 2012-11702 Filed 5-14-12; 8:45 am]

**BILLING CODE 4162-20-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Fiscal Year (FY) 2012 Funding Opportunity

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice of intent to award a single source grant to the Natividad Medical Center in Salinas, CA.

**SUMMARY:** This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) intends to award approximately \$375,000 (total costs) for

up to one year to the Natividad Medical Center in Salinas, CA. This is not a formal request for applications.

Assistance will be provided only to the Natividad Medical Center based on the receipt of a satisfactory application that is approved by an independent review group.

*Funding Opportunity Title:* TI-12-009.

*Catalog of Federal Domestic Assistance (CFDA) Number:* 93.243.

*Authority:* Section 509 of the Public Health Service Act, as amended.

*Justification:* Only the Natividad Medical Center in Salinas, CA is eligible to apply. The Substance Abuse and Mental Health Services Administration (SAMHSA) is seeking to award a supplemental grant to the Natividad Medical Center in Salinas, CA, to enable Natividad to continue to develop and implement a training program to teach medical residents skills to provide evidence-based screening, brief intervention, brief treatment and referral to specialty treatment for patients who have, or are at risk for, a substance use disorder as required under the FY 2008 Request for Applications (RFA). This organization was funded under the SBIRT Medical Residency grant program (TI-08-003) in FY 2008. Under the leadership at that time, the Natividad Medical Center received a 4-year grant, although the SBIRT Medical Residency Program is a 5-year program.

Subsequent to the original award, new leadership for the grant program has been put in place. As a result, the new leadership has determined that in order to execute the full requirements of the program and to meet the necessary client targets, the final year of funding is required. The purpose of this sole source award is to fund the last year of the 5-year cooperative agreement awarded under the initial announcement. SAMHSA will not accept an application from any other entity. Natividad Medical Center is in the unique position to be awarded one year funding because:

- Natividad Medical Center to date has successfully implemented the SBIRT Medical Residency Program since 2008, and a fifth year of funding would give the program an additional year to train more residents in SBIRT as well as allow the program to solidify sustaining its training program after the end of SAMHSA funding.

- Natividad Medical Center is the only SBIRT Medical Residency Program grantee in Central California, and serves minority, high-risk and vulnerable populations, including farm workers, low-income individuals, adolescents, elderly, homeless, veterans, and

individuals with substance abuse and co-occurring disorders.

*Contact:* Cathy Friedman, Substance Abuse and Mental Health Services Administration, 1 Choke Cherry Road, Room 8-1097, Rockville, MD 20857; telephone: (240) 276-2316; Email: [cathy.friedman@samhsa.hhs.gov](mailto:cathy.friedman@samhsa.hhs.gov).

**Cathy Friedman,**

*SAMHSA Public Health Analyst.*

[FR Doc. 2012-11725 Filed 5-14-12; 8:45 am]

**BILLING CODE 4162-20-P**

## DEPARTMENT OF HOMELAND SECURITY

### Federal Emergency Management Agency

[Docket ID: FEMA-2012-0020; OMB No. 1660-0009]

**Agency Information Collection Activities: Submission for OMB review; Comment Request; The Declaration Process: Requests for Damage Assessment, Federal Disaster Assistance, Appeals, Cost Share Adjustment**

**AGENCY:** Federal Emergency Management Agency, DHS.

**ACTION:** Notice.

**SUMMARY:** The Federal Emergency Management Agency (FEMA) is submitting a request for review and approval of a collection of information under the emergency processing procedures in Office of Management and Budget (OMB) regulation 5 CFR 1320.13. FEMA is requesting that this information collection be approved by June 1, 2012. The approval will authorize FEMA to use the collection through December 1, 2012. FEMA plans to follow this emergency request with a request for a 3-year approval. The request will be processed under OMB's normal clearance procedures in accordance with the provisions of OMB regulation 5 CFR 1320.10. To help us with the timely processing of the emergency and normal clearance submissions to OMB, FEMA invites the general public to comment on the proposed collection of information.

**DATES:** Comments must be submitted to OMB on or before June 14, 2012. You may submit comments to FEMA on or before July 16, 2012.

**ADDRESSES:** Submit written comments on the proposed information collection to the Office of Information and Regulatory Affairs, Office of Management and Budget. Comments should be addressed to the Desk Officer for the Department of Homeland